Milestone Pharmaceuticals Inc.
US ˙ NasdaqGS ˙ CA59935V1076

SecurityMIST / Milestone Pharmaceuticals Inc.
InstitutionRenaissance Technologies Llc
ManagerJames Simons
Latest Disclosed Ownership129,705 shares
Latest Disclosed Value $ 154,349
Renaissance Technologies Llc ownership in MIST / Milestone Pharmaceuticals Inc.

On May 14, 2026 - Renaissance Technologies Llc filed a 13F-HR form disclosing ownership of 129,705 shares of Milestone Pharmaceuticals Inc. (US:MIST) valued at $154,349 USD as of March 31, 2026. The entity filed a previous 13F-HR on November 14, 2023 disclosing 0 shares of Milestone Pharmaceuticals Inc.. The current value of the position is $167,319 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F MILESTONE PHARMACEUTICALS IN COM 59935V107 129,705 129,705 154 0.0002
2023-11-14 2023-09-30 13F MILESTONE PHARMACEUTICALS IN COM 59935V107 0 -108,766 -100.00 0 0.0000
2023-08-11 2023-06-30 13F MILESTONE PHARMACEUTICALS IN COM 59935V107 108,766 16,966 18.48 0 0.0004
2023-05-12 2023-03-31 13F MILESTONE PHARMACEUTICALS IN COM 59935V107 91,800 24,600 36.61 0 0.0005
2023-02-13 2022-12-31 13F MILESTONE PHARMACEUTICALS IN COM 59935V107 67,200 67,200 0 0.0004
2022-02-11 2021-12-31 13F MILESTONE PHARMACEUTICALS IN COM 59935V107 0 -26,400 -100.00 0 -100.00
2021-11-12 2021-09-30 13F MILESTONE PHARMACEUTICALS IN COM 59935V107 26,400 -81,154 -75.45 151 -74.49 0.0002
2021-08-13 2021-06-30 13F MILESTONE PHARMACEUTICALS IN COM 59935V107 107,554 -108,846 -50.30 592 -52.75 0.0007
2021-05-13 2021-03-31 13F MILESTONE PHARMACEUTICALS IN COM 59935V107 216,400 52,400 31.95 1,253 14.01 0.0016
2021-02-10 2020-12-31 13F MILESTONE PHARMACEUTICALS IN COM 59935V107 164,000 148,900 986.09 1,099 890.09 0.0012
2020-11-13 2020-09-30 13F MILESTONE PHARMACEUTICALS IN COM 59935V107 15,100 15,100 111 0.0001
2020-08-13 2020-06-30 13F MILESTONE PHARMACEUTICALS IN COM 59935V107 0 -10,242 -100.00 0 -100.00
2020-05-14 2020-03-31 13F MILESTONE PHARMACEUTICALS IN COM 59935V107 10,242 10,242 19 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.